Raymond Blind, PhD

Profile

The Blind Lab Website

Publications

The following timeline graph is generated from all co-authored publications.

1. Human islets expressing HNF1A variant have defective β cell transcriptional regulatory networks. Haliyur R, Tong X, Sanyoura M, Shrestha S, Lindner J, Saunders DC, Aramandla R, Poffenberger G, Redick SD, Bottino R, Prasad N, Levy SE, Blind RD, Harlan DM, Philipson LH, Stein RW, Brissova M, Powers AC (2019) J Clin Invest 129(1): 246-251
   › Primary publication · 30507613 (PubMed) · PMC6307934 (PubMed Central)
2. Crystallographic and kinetic analyses of human IPMK reveal disordered domains modulate ATP binding and kinase activity. Seacrist CD, Blind RD (2018) Sci Rep 8(1): 16672
   › Primary publication · 30420721 (PubMed) · PMC6232094 (PubMed Central)
3. Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease. Bryant JM, Blind RD (2019) J Lipid Res 60(2): 299-311
   › Primary publication · 30201631 (PubMed) · PMC6358298 (PubMed Central)
4. Nuclear phosphoinositide regulation of chromatin. Hamann BL, Blind RD (2018) J Cell Physiol 233(1): 107-123
   › Primary publication · 28256711 (PubMed)
5. Phospholipid regulation of the nuclear receptor superfamily. Crowder MK, Seacrist CD, Blind RD (2017) Adv Biol Regul : 6-14
   › Primary publication · 27838257 (PubMed) · PMC5292085 (PubMed Central)
6. Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolism. Malabanan MM, Blind RD (2016) Biochem Soc Trans 44(1): 279-85
   › Primary publication · 26862216 (PubMed) · PMC5380233 (PubMed Central)
7. Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket. Sablin EP, Blind RD, Uthayaruban R, Chiu HJ, Deacon AM, Das D, Ingraham HA, Fletterick RJ (2015) J Struct Biol 192(3): 342-348
   › Primary publication · 26416531 (PubMed) · PMC4651778 (PubMed Central)
8. The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1. Blind RD, Sablin EP, Kuchenbecker KM, Chiu HJ, Deacon AM, Das D, Fletterick RJ, Ingraham HA (2014) Proc Natl Acad Sci U S A 111(42): 15054-9
   › Primary publication · 25288771 (PubMed) · PMC4210282 (PubMed Central)
9. Disentangling biological signaling networks by dynamic coupling of signaling lipids to modifying enzymes. Blind RD (2014) Adv Biol Regul : 25-38
   › Primary publication · 24176936 (PubMed) · PMC3946453 (PubMed Central)
10. Direct modification and activation of a nuclear receptor-PIP₂ complex by the inositol lipid kinase IPMK. Blind RD, Suzawa M, Ingraham HA (2012) Sci Signal 5(229): ra44
    › Primary publication · 22715467 (PubMed) · PMC3395721 (PubMed Central)
11. Ligand structural motifs can decouple glucocorticoid receptor transcriptional activation from target promoter occupancy. Blind RD, Pineda-Torra I, Xu Y, Xu HE, Garabedian MJ (2012) Biochem Biophys Res Commun 420(4): 839-44
    › Primary publication · 22465009 (PubMed) · PMC3340612 (PubMed Central)
12. Applying innovative educational principles when classes grow and resources are limited: Biochemistry experiences at Muhimbili University of Allied Health Sciences. Omer S, Hickson G, Taché S, Blind R, Masters S, Loeser H, Souza K, Mkony C, Debas H, O'Sullivan P (2008) Biochem Mol Biol Educ 36(6): 387-94
    › Primary publication · 21591227 (PubMed)
13. Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, Williams SP, Willson TM, Xu R, Zuercher WJ, Cai F, Ingraham HA (2011) J Med Chem 54(7): 2266-81
    › Primary publication · 21391689 (PubMed) · PMC4151520 (PubMed Central)
14. Regulation of C. elegans fat uptake and storage by acyl-CoA synthase-3 is dependent on NR5A family nuclear hormone receptor nhr-25. Mullaney BC, Blind RD, Lemieux GA, Perez CL, Elle IC, Faergeman NJ, Van Gilst MR, Ingraham HA, Ashrafi K (2010) Cell Metab 12(4): 398-410
    › Primary publication · 20889131 (PubMed) · PMC2992884 (PubMed Central)
15. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA (2009) Cancer Res 69(13): 5415-23
    › Primary publication · 19549922 (PubMed) · PMC2756996 (PubMed Central)
16. Structure of SF-1 bound by different phospholipids: evidence for regulatory ligands. Sablin EP, Blind RD, Krylova IN, Ingraham JG, Cai F, Williams JD, Fletterick RJ, Ingraham HA (2009) Mol Endocrinol 23(1): 25-34
    › Primary publication · 18988706 (PubMed) · PMC2646595 (PubMed Central)
17. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ (2008) Mol Endocrinol 22(8): 1754-66
    › Primary publication · 18483179 (PubMed) · PMC2725771 (PubMed Central)
18. Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes. Blind RD, Garabedian MJ (2008) J Steroid Biochem Mol Biol 109(1-2): 150-7
    › Primary publication · 18304804 (PubMed) · PMC2699583 (PubMed Central)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword